Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Breakout support ⢠Overbought risk Support Level: $214.85-$215.15 Resistance Level: $227.90 DGX is in a strong short-term uptrend near $227.90, but the fast move from last month's $206.84 area leaves it stretched and vulnerable to a pause unless it holds above $215.
Sentiment & News
Key News Insights: ⢠Q2 Beat ⢠Guidance Raise ⢠Demand Broadening Quest Diagnostics posted a Q2 beat, raised 2026 guidance, and is seeing broadening preventive and specialty testing demand that has lifted the stock to new highs.
AI Summary
DGX has shifted from a defensive healthcare compounder to a âprove-itâ growth story after strong Q2 results and raised guidance, but with the stock already re-rated to a premium and new debt added, the key takeaway is that upside now depends on Quest sustaining double-digit growth and holding the breakout near $215 rather than merely meeting expectations.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |